CLOROX COMPANY (CLX)       151.69  -0.88 (-0.58%)

151.69  -0.88 (-0.58%)

US1890541097 - Common Stock - After market: 151.69 0 (0%)


Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CLX. CLX was compared to 12 industry peers in the Household Products industry. CLX has a medium financial health rating, its profitability is only medium as well. While showing a medium growth rate, CLX is valued expensive at the moment.




Profitability

Profitability Rating

4

CLX's Return On Equity of 135.51% is amongst the best of the industry. CLX does better than the industry average Return On Equity of 14.24%.
CLX's Return On Assets of 7.20% is in line with the rest of the industry. The industry average Return On Assets is 5.21%.

The Piotroski-F score of CLX is 6.00. This is a neutral score and indicates average health and profitability for CLX.
CLX's Profit Margin of 6.16% is worse than the rest of the industry. The industry average Profit Margin is 6.82%.
VS Industry

ROA (7.2%) VS Industry: 60% outperformed.

1.24
14.16

ROE (135.51%) VS Industry: 80% outperformed.

5.67
445.14

Profit Margin (6.16%) VS Industry: 40% outperformed.

2.29
17.44

Valuation

Valuation Rating

0

With a Price/Earnings Ratio of 36.55, CLX can be considered very expensive at the moment.
With a Price/Earning Ratio of 36.55, CLX is valued a higher than the industry average, which is at 24.73. 82% of the companies listed in the same industry are cheaper than CLX!
With a Forward Price/Earnings Ratio of 28.03, CLX is valued very expensively.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

When comparing the current price to the book value of CLX, we can conclude it is valued rather expensively. It is trading at 58.37 times its book value.
Compared to an average industry price book ratio of 7.43, CLX is valued more expensive than its industry peers. 82% of the companies listed in the same industry are valued cheaper.
Compared to an average industry Enterprise Value to EBITDA ratio of 16.40, CLX is valued more expensive than its industry peers.
VS Industry

Price/Earnings (36.55) VS Industry: 18% outperformed.

48.20
11.44

Price/Book (58.37) VS Industry: 18% outperformed.

152.98
1.63

Enterprise Value/ EBITDA (22.77) VS Industry: 27% outperformed.

29.33
8.99

Growth

Growth Rating

4

Based on estimates for the next 5 years, CLX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.46% on average per year.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The earnings per share for CLX have decreased by -6.53% in the last year.
CLX shows a decrease in Earnings Per Share. Measured over the last 5 years, the EPS has been decreasing by -5.31% yearly.

CLX shows a decrease in Revenue. In the last year, the revenue decreased by -0.21%.
CLX shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 3.54% yearly.
CLX is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 2.89% yearly.
The Revenue growth is stable: in the next 5 years the growth will be about the same than in the last 5 years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-5.31% -13.45% -6.53% 2.92% 14.75% 15.54% 15.46%
Revenue3.54% 4.58% -0.21% -1.31% 0.85% 1.6% 2.89%

Health

Health Rating

4

CLX has an Altman-Z score of 3.66. This indicates that CLX is financially healthy and little risk of bankruptcy at the moment.
When comparing the Altman-Z score to an average industry score of 2.72, CLX is in better financial health than the average industry peer.
The Piotroski-F score of CLX is 6.00. This is a neutral score and indicates average health and profitability for CLX.
A Current Ratio of 0.86 indicates that CLX may have some problems paying its short term obligations.

Compared to an average industry Current Ratio of 2.25, CLX is worse placed to pay its short term obligations than its industry peers. 82% of its industry peers have a better Current Ratio.
CLX has a Quick Ratio of 0.86. This is a bad value and indicates that CLX is not financially healthy enough and could expect problems in meeting its short term obligations.
Compared to an average industry Quick Ratio of 1.17, CLX is worse placed to pay its short term obligations than its industry peers. 91% of its industry peers have a better Quick Ratio.
When comparing the Debt to Equity Ratio of CLX to the average industry Debt to Equity Ratio of 1.15, CLX required more debt to finance its operations than its industry peers.
VS Industry

Debt/Equity (7.71) VS Industry: 27% outperformed.

26.79
0.21

Quick Ratio (0.47) VS Industry: 9% outperformed.

0.37
2.07

Current Ratio (0.86) VS Industry: 18% outperformed.

0.56
3.34

Altman-Z (3.66) VS Industry: 62% outperformed.

1.46
9.34

Dividend

Dividend Rating

6

CLX's Dividend Yield is a higher than the industry average which is at 3.03.
Compared to an average S&P500 Dividend Yield of 2.41, CLX pays a bit more dividend than the S&P500 average.
The dividend of CLX is nicely growing with an annual growth rate of 6.51%!
The dividend of CLX is growing, but earnings are growing more, so the dividend growth is sustainable.

CLX has been paying a dividend for at least 10 years, so it has a reliable track record.
CLX has a Yearly Dividend Yield of 3.05%. Purely for dividend investing, there may be better candidates out there.
132.64% of the earnings are spent on dividend by CLX. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (3.05%) VS Industry: 62% outperformed.

1.31
3.43

CLOROX COMPANY151.69

NYSE:CLX (2/7/2023, 7:04:00 PM)-0.88 (-0.58%)

After market: 151.69 0 (0%)

Chartmill FA Rating
GICS Sector Consumer Staples
GICS IndustryGroup Household & Personal Products
GICS Industry Household Products
Earnings (Last) 02-02 2023-02-02/amc Earnings (Next) 05-01 2023-05-01/amc
Inst Owners 79.69% Inst Owner Change -55.99%
Ins Owners 0.15% Ins Owner Change 21.65%
Market Cap 18.74B Analysts 49.29
Price Target 139.3 (-8.17%)

Dividend
Industry RankSector Rank
Dividend Yield 3.05%
Dividend Growth(5Y) 6.51% DP 132.64%
Div Incr Years 19 Div Non Decr Years 19
Ex-Date 01-24 2023-01-24 (1.18)

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 36.38%
Min EPS beat(2) 23.91% Max EPS beat(2) 48.85%
EPS beat(4) 3 Avg EPS beat(4) 26.27%
Min EPS beat(4) -0.93% Max EPS beat(4) 48.85%
Revenue beat(2) 2 Avg Revenue beat(2) 2.1%
Min Revenue beat(2) 1.75% Max Revenue beat(2) 2.45%
Revenue beat(4) 2 Avg Revenue beat(4) -0.03%
Min Revenue beat(4) -4.15% Max Revenue beat(4) 2.45%
PT rev (1m) 1.11% PT rev (3m) 5.47%
EPS NQ rev (1m) 0.05% EPS NQ rev (3m) 2.44%
EPS NY rev (1m) 0% EPS NY rev (3m) 2.97%
Revenue NQ rev (1m) -0.38% Revenue NQ rev (3m) 0.23%
Revenue NY rev (1m) 0% Revenue NY rev (3m) 0.12%

Valuation
Industry RankSector Rank
PE 36.55
Fwd PE 28.03
P/S 2.65
P/FCF 25.99
P/OCF 19.7
P/B 58.37
P/tB N/A
EV/EBITDA 22.77
EPS(TTM) 4.15 EY 2.74%
EPS(NY) 5.41 Fwd EY 3.57%
FCF(TTM) 5.84 FCFY 3.85%
OCF(TTM) 7.7 OCFY 5.08%
SpS 57.19 BVpS 2.6
TBVpS -17 PEG (NY) 12.54
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA 7.2%
ROE 135.51%
ROIC 12.61%
ROICexc 13.12%
ROICexgc 30.89%
OM 9.92%
PM 6.16%
GM 36.26%
ROICexgc(3y) 54.18% ROICexcg growth 3Y -22.2%
ROICexcg growth 5Y -23.1% ROICexc(3y) 20.8%
ROICexc growth 3Y -16.9% ROICexc growth 5Y -16.8%
OM growth 3Y -17.53% OM growth 5Y -11.61%
PM growth 3Y -21.02% PM growth 5Y -11.14%
GM growth 3Y -6.57% GM growth 5Y -4.35%
F-Score 6 Asset Turnover 1.17

Health
Industry RankSector Rank
Debt/Equity 7.71
Debt/FCF 3.72
Debt/EBITDA 2.89
Cap/Depr 100.88%
Profit Quality 165.75%
Current Ratio 0.86
Quick Ratio 0.47
Altman-Z 3.66
F-Score 6 WACC 7.53%
ROIC/WACC 4.1 Cap/Depr(3y) 136.68%
Cap/Depr(5y) 128.27% Profit Quality(3y) 128.83%
Profit Quality(5y) 115.42%

Growth
EPS 1Y -6.53% EPS 3Y -13.45%
EPS 5Y -5.31% EPS growth Q2Q 48.48%
EPS Next Y 2.92% EPS Next 2Y 14.75%
EPS Next 3Y 15.54% EPS Next 5Y 15.46%
Revenue growth 1Y -0.21% Revenue growth 3Y 4.58%
Revenue growth 5Y 3.54% Revenue growth Q2Q 1.42%
Revenue Next Year -1.31% Revenue Next 2Y 0.85%
Revenue Next 3Y 1.6% Revenue Next 5Y 2.89%
EBIT growth 1Y -6.16% EBIT growth 3Y -13.76%
EBIT growth 5Y -8.48% EBIT Next Year 35.8%
EBIT Next 3Y 21.56% EBIT Next 5Y 16.18%
FCF growth 1Y -47.87% FCF growth 3Y -12.03%
FCF growth 5Y -3.43% OCF growth 1Y -43.29%
OCF growth 3Y -7.47% OCF growth 5Y -1.97%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA